In 2022, Lekhim JSC (Kyiv) reduced its net profit by 36.5% compared to 2021, to UAH 247.308 million.
According to the company’s announcement in the NSSMC’s information disclosure system, the performance indicators will be considered by its shareholders at an extraordinary meeting on December 4.
In addition, the shareholders plan to amend the corporate governance system and re-elect Valeriy Pechaev as Chairman of the Board of Directors, Tatyana Pechaeva as Deputy Chairman of the Board, Olga Pechaeva as Chief Executive Officer, and Valentina Mazuryk, Lesya Redkina, Lyubov Lazko, and Svetlana Pechaeva as members of the Board of Directors.
Lekhim JSC owns 100% of Lekhim-Obukhov LLC, 98.2% of Lekhim Kharkiv PrJSC, 81% of Technolog (Cherkasy region), 100% of Lekhim-Vilnius CJSC and 100% of Lekhim’s foreign representative office in Uzbekistan.
Lekhim produces more than 200 medicinal products of almost all therapeutic groups, and annually registers more than 10 new drugs. its products are exported to more than 35 countries. One of Lekhim’s anti-tuberculosis drugs is prequalified by the WHO.
As reported, in 2023, Lekhim Group of Pharmaceutical Companies signed a sublicense agreement with the Medicines Patent Pool (MPP) for the production of a generic version of the innovative Japanese antiviral drug Ensitrelvir manufactured by Shionogi, which can be used to treat COVID-19. Seven pharmaceutical companies signed sublicense agreements, and Lekhim is the only Ukrainian pharmaceutical manufacturer among them. In addition, the agreement was signed by three generic pharmaceutical manufacturers from China, two companies from India and a company from Vietnam.
